Biktarvy Side Effects: Complete Guide for Patients (2026)

If you have recently been prescribed Biktarvy — or are weighing it against other options — understanding its side effect profile is essential. The short answer is reassuring: Biktarvy is one of the best-tolerated HIV regimens ever studied, with fewer than 1% of patients stopping treatment due to side effects over five years. But every patient is different, and knowing what to watch for helps you stay ahead of any problems.

This guide covers every known side effect — common, uncommon, and serious — along with what causes them, how long they last, which drug interactions to avoid, and what your doctor should be monitoring. All data comes from Gilead's five-year SOLSTICE and GS-US-380-1489 clinical program and the current FDA prescribing information for Biktarvy.

Common Side Effects of Biktarvy

In the pivotal Phase 3 clinical trials, the following side effects occurred in at least 5% of patients taking Biktarvy. All were considered mild to moderate in severity.

• Diarrhea — reported in approximately 7% of patients. Usually loose stools rather than frequent watery diarrhea. Often improves spontaneously after the first few weeks.
• Nausea — reported in approximately 6% of patients. Most common in the first week or two. Taking Biktarvy with food significantly reduces this effect.
• Headache — reported in approximately 6% of patients. Typically mild and resolves without any intervention.
• Fatigue — reported in around 4% of patients. Often difficult to distinguish from HIV-related fatigue, which itself improves as viral load is suppressed.
• Abnormal dreams — reported in approximately 3% of patients. More common in the first month and usually subsides.
• Dizziness — reported in approximately 3% of patients. Rare reason for stopping treatment.

Full Biktarvy Side Effects Table

Weight Gain and Metabolic Effects

Weight gain is one of the most discussed side effects of integrase inhibitor-based regimens, including Biktarvy. In clinical trials of treatment-naive patients, average weight increased by approximately 2–3 kg at week 48. In longer-term studies, some patients gained more.

The cause is not fully understood. Research suggests it is partly a class effect of integrase inhibitors and partly immune reconstitution weight recovery — patients who were underweight due to untreated HIV regain healthy mass as their immune system recovers. This is not necessarily a problem.

However, for patients with pre-existing obesity, diabetes risk, or cardiovascular disease, clinically significant weight gain should be monitored and managed. If weight gain becomes a concern, your doctor may consider switching to a regimen with a different metabolic profile — but this decision requires careful clinical judgment to avoid losing viral suppression.

Lipid changes

Modest increases in total cholesterol, LDL, and triglycerides have been observed in some patients. These are generally small and unlikely to require lipid-lowering therapy in most people, but routine lipid monitoring remains part of standard HIV care. Statin interactions can occur — discuss any new lipid medication with your HIV doctor before starting.

Kidney and Bone Safety

Biktarvy contains tenofovir alafenamide (TAF) rather than the older tenofovir disoproxil fumarate (TDF) used in earlier HIV regimens. This distinction matters significantly for kidney and bone safety.

Kidneys

TAF delivers tenofovir directly to immune cells at much lower plasma concentrations than TDF. The result is a dramatically improved kidney safety profile. In head-to-head trials, Biktarvy produced significantly smaller declines in estimated glomerular filtration rate (eGFR) and lower rates of tubular toxicity biomarkers compared to TDF-containing regimens.

That said, Biktarvy is still not recommended for patients with eGFR below 30 mL/min who are not on dialysis, and routine renal monitoring is standard practice. For patients with existing kidney disease, your HIV specialist and nephrologist should coordinate care.

Bone density

TDF-based regimens are associated with measurable decreases in bone mineral density — a concern for older patients and those at fracture risk. TAF in Biktarvy produces significantly smaller bone density changes. In patients who switched from TDF-based regimens to Biktarvy, bone density measurements often improved over time, which is clinically meaningful for long-term HIV management.

Serious Side Effects and Boxed Warnings

The FDA prescribing information for Biktarvy carries a boxed warning — the most serious warning the FDA issues — covering two distinct situations.

Lactic acidosis and severe hepatomegaly with steatosis

This is a class effect of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), the drug class to which emtricitabine and tenofovir alafenamide belong. Lactic acidosis is an accumulation of lactic acid in the blood and can be life-threatening. Cases are rare but have been reported with all NRTI-containing regimens.

Post-treatment hepatitis B exacerbation

All three components of Biktarvy — bictegravir, emtricitabine, and tenofovir alafenamide — have activity against hepatitis B virus (HBV). This means that if a patient co-infected with both HIV and HBV abruptly stops Biktarvy, the sudden loss of HBV suppression can trigger a severe and potentially life-threatening hepatitis B flare.

If you are HBV co-infected and need to stop or switch Biktarvy for any reason, this must be done under close medical supervision with liver function monitoring for several months after discontinuation.

Drug Interactions to Know

Bictegravir, the integrase inhibitor in Biktarvy, is metabolized by the CYP3A and UGT1A1 enzymes. This creates several important drug interactions that every patient should be aware of.

Contraindicated drugs (must NOT be taken with Biktarvy)

• Rifampin — a potent CYP3A inducer used to treat tuberculosis and other infections. Reduces bictegravir plasma levels by approximately 75%, rendering Biktarvy ineffective. Do not co-administer. Patients with HIV/TB co-infection require a different antiretroviral strategy — discuss with your specialist.
• Dofetilide — a cardiac antiarrhythmic. Bictegravir inhibits renal transporters that clear dofetilide, leading to dangerously elevated dofetilide levels and risk of serious cardiac arrhythmia.

Drugs to use with caution or avoid

• Rifabutin — reduces bictegravir levels substantially (approximately 38% AUC reduction). Not recommended. If rifabutin is necessary, discuss alternatives with your HIV specialist.
• St. John's Wort — a commonly used herbal supplement. Strong CYP3A inducer that can significantly reduce bictegravir levels. Do not use while on Biktarvy.
• Antacids and supplements containing aluminum, magnesium, iron, or calcium — metal cations chelate bictegravir in the gut and reduce absorption. Separate Biktarvy from these products by at least 2 hours before or after. This includes common antacids (Maalox, Tums), iron supplements, and many multivitamins.
• Metformin — Biktarvy can increase metformin plasma levels. If you are diabetic and taking metformin, your doctor should monitor for metformin toxicity and may need to adjust the metformin dose.

How Long Do Biktarvy Side Effects Last?

For the vast majority of patients, early side effects are temporary. The typical timeline:

• Week 1–2: Nausea and headache are most likely to occur. Taking Biktarvy with food significantly reduces nausea during this window.
• Week 2–4: Most GI side effects (diarrhea, nausea) resolve as the body adjusts. Abnormal dreams and dizziness also typically improve.
• Beyond week 4: Most patients report no ongoing side effects. Fatigue often improves substantially as viral load is suppressed and immune function recovers over the first several months.
• Weight and metabolic changes: These are ongoing and require monitoring at routine HIV care visits rather than at a specific endpoint.

If significant side effects persist beyond four to six weeks, or if any new symptoms develop at any point, speak with your HIV care provider. There are good clinical reasons to either adjust timing of the dose, add supportive medications, or — in rare cases — consider an alternative regimen.

What Your Doctor Should Monitor

The following tests are standard for patients on Biktarvy, as recommended by HIV treatment guidelines from the DHHS and IAS–USA:

• HIV viral load — at 4–8 weeks after starting, then every 3–6 months once suppressed. The target is undetectable (<50 copies/mL).
• CD4 count — every 3–6 months in the first year, then annually once stable and suppressed.
• Renal function (creatinine, eGFR, urinalysis) — at baseline, 2–4 weeks after starting, then every 6–12 months. More frequent if pre-existing kidney disease exists.
• Liver function tests (ALT, AST) — at baseline and periodically, especially if HBV co-infected.
• Lipid panel (total cholesterol, LDL, HDL, triglycerides) — at baseline then annually.
• Fasting glucose and HbA1c — as part of cardiovascular risk assessment, particularly in older patients or those with diabetes risk factors.
• Bone density (DEXA scan) — recommended for patients over 50, post-menopausal women, or those with fragility fracture history.
• Hepatitis B serology — must be done before starting Biktarvy. If positive for HBV, close monitoring is required indefinitely.
• Body weight — at every visit. Trend over time is more informative than any single measurement.

Common Mistakes Patients Make with Biktarvy Side Effects

Stopping the medication without telling their doctor

This is the most dangerous mistake, particularly for patients co-infected with hepatitis B. Even in patients without HBV, stopping Biktarvy suddenly can allow viral rebound, risk transmission, and reduce future treatment options if resistance develops (though resistance with Biktarvy is extremely rare). Always call your provider before stopping.

Attributing ongoing fatigue to Biktarvy when another cause is more likely

Fatigue is a common human experience and has many causes — sleep quality, depression, anaemia, thyroid issues, and others all need to be considered. Many patients attribute persistent fatigue to Biktarvy when the actual cause is unrelated and treatable. If fatigue is an issue, ask your doctor for a full workup rather than assuming it's the medication.

Taking antacids or supplements at the same time as Biktarvy

A very common and easily avoidable interaction. Multivitamins, iron tablets, calcium supplements, and over-the-counter antacids should all be separated from Biktarvy by at least two hours. Patients who routinely take these products should build this separation into their daily routine.

Not disclosing Biktarvy to new prescribers

Drug interactions can occur when seeing an urgent care clinic, a new specialist, or a dentist. Always mention Biktarvy — or better yet, carry a full medication list. The rifampin interaction in particular can occur during TB or MAC treatment, and the dofetilide interaction in cardiac care, in settings where the prescriber may not be thinking about HIV drug interactions.

Assuming weight gain is always a problem

Some patients become alarmed by early weight gain and consider stopping treatment. In most cases, especially in the first year, modest weight gain reflects immune reconstitution and return of appetite — both healthy signs. Work with your care team to distinguish normal recovery from metabolically problematic weight change.

Frequently Asked Questions

Final Thoughts

Biktarvy's side effect profile is, by any clinical measure, excellent. Fewer than 1% of patients stop it due to adverse events over five years — a figure that puts it among the best-tolerated HIV regimens ever studied. Most of what patients experience in the first few weeks (nausea, headache, loose stools) resolves on its own, and the kidney and bone safety advantages over older TDF-based therapy are real and well-documented.

That said, no medication is risk-free. The hepatitis B co-infection warning is serious and mandatory knowledge for every HBV-positive patient on Biktarvy. Drug interactions — particularly with rifampin, dofetilide, and antacids — require ongoing awareness as your other medications change over time.

The most important thing you can do is stay engaged with your HIV care team, attend monitoring visits, and never stop or change Biktarvy without talking to your prescriber first. The five-year data showing 98.6% viral suppression with zero treatment-emergent resistance is only achievable because patients stay on therapy. Side effects are a reason to talk to your doctor — not a reason to stop on your own.

For information on what Biktarvy costs and how to access financial assistance, see our guide to Biktarvy generic options and cost access programs.